Announcement on Abnormal Stock Trading Volatility of Hunan Jingfeng Pharmaceutical Co., Ltd.

MaticHoleFiller · 2026-03-18T22:13:06+00:00

Hunan Jingfeng Pharmaceutical's announcement indicates that its stock will apply to revoke the delisting risk warning due to the completion of the restructuring plan, but it is still uncertain whether this will be approved in the future. Recently, the company's stock price has experienced abnormal fluctuations, and the board of directors confirms that there are no undisclosed major matters. Risk warnings include the possibility of continued implementation of other risk alerts in the future, and it is expected that the company will still incur losses in 2025.

MaticHoleFiller

2026-03-18 22:13:06

Abstract generation in progress

Securities Code: 000908
Stock Abbreviation: *ST Jingfeng
Announcement No.: 2026-022

Hunan Jingfeng Pharmaceutical Co., Ltd.

Announcement on Abnormal Fluctuations in Stock Trading

Our company and all members of the board of directors guarantee that the information disclosed is true, accurate, and complete, with no false records, misleading statements, or major omissions.

Special Risk Reminder:

Since the restructuring plan of Hunan Jingfeng Pharmaceutical Co., Ltd. (hereinafter referred to as “the Company”) has been completed, the company will apply to the Shenzhen Stock Exchange for the withdrawal of the delisting risk warning triggered by the acceptance of restructuring by the Changde Intermediate People’s Court of Hunan Province (hereinafter referred to as “Changde Court”) in accordance with the relevant provisions of the “Shenzhen Stock Exchange Stock Listing Rules” (hereinafter referred to as “Stock Listing Rules”). Whether the application will be approved by the Shenzhen Stock Exchange remains uncertain.
The lowest of the net profits before and after deducting non-recurring gains and losses for 2022, 2023, and 2024 is negative. Additionally, Daxin Certified Public Accountants (Special General Partnership) issued an unqualified audit report with a paragraph on significant uncertainties related to the company’s ongoing operations for the 2024 financial report. The company may be subject to other risk warnings as stipulated in Article 9.8.1, Item (7) of the “Stock Listing Rules.” As of the date of this announcement, the impact of the “Major Uncertainty Related to Continuing Operations” in the 2024 annual audit report has not been eliminated.

Given that the company is subject to other risk warnings (ST), if the application for delisting risk warning due to restructuring is approved by the Shenzhen Stock Exchange, the company’s stock will continue to be under other risk warning (ST), and the stock abbreviation will be changed to “ST Jingfeng.” The daily price fluctuation limit remains at 5%.

I. Introduction to Abnormal Stock Trading Fluctuations

The company’s stock (Stock Abbreviation: *ST Jingfeng, Stock Code: 000908) experienced a cumulative deviation of 16.87% in closing prices over three consecutive trading days on March 11, 12, and 13, 2026. According to relevant provisions of the “Shenzhen Stock Exchange Trading Rules,” this constitutes an abnormal trading fluctuation.

II. Explanation of Company Attention and Verification

In response to the abnormal fluctuations in the company’s stock, the company has conducted verification and provides the following explanation:

The information previously disclosed by the company does not require correction or supplementation.
The company has not found recent media reports of undisclosed major information that could significantly impact the company’s stock trading price.
The company’s recent operations are normal, and there have been no major changes in the internal or external operating environment.
After verification with management, controlling shareholders, and actual controllers, the company, controlling shareholders, and actual controllers have no undisclosed major matters nor are they planning any major matters.
During the attention and verification process, no other disclosures were found to be necessary.
The company has no undisclosed matters that could lead to abnormal stock trading fluctuations.

III. Explanation of No Need for Disclosure of Information

The company’s board of directors confirms that there are currently no matters that should be disclosed according to the “Stock Listing Rules” or related regulations, nor any planning, negotiations, intentions, or agreements related to such matters. The board has not become aware of any information that should be disclosed but has not been disclosed, which could significantly affect the trading prices of the company’s stocks and derivatives. The previously disclosed information does not require correction or supplementation.

IV. Risk Reminder

After self-examination, the company confirms that it has not violated fair disclosure of information.
Since the restructuring plan has been completed, the company will apply to the Shenzhen Stock Exchange for the withdrawal of the delisting risk warning triggered by the acceptance of restructuring by the Changde Court. Whether this application will be approved remains uncertain.
The lowest net profit for 2022, 2023, and 2024 before and after deducting non-recurring gains and losses is negative. Additionally, Daxin Certified Public Accountants issued an unqualified audit report with a paragraph on significant uncertainties related to ongoing operations for 2024. The company may be subject to other risk warnings as stipulated in Article 9.8.1, Item (7) of the “Stock Listing Rules.” As of this announcement, the impact of the “Major Uncertainty Related to Continuing Operations” in the 2024 annual audit report has not been eliminated.

Given the company’s situation of being subject to other risk warnings (ST), if the application for delisting risk warning due to restructuring is approved by the Shenzhen Stock Exchange, the stock will continue to be under other risk warning (ST), and the stock abbreviation will be changed to “ST Jingfeng,” with a daily price fluctuation limit of 5%.

On January 30, 2026, the company disclosed the “2025 Annual Performance Forecast” (Announcement No.: 2026-009), estimating that the net profit attributable to shareholders of the listed company for 2025 will be negative, with a loss of 60 million to 90 million yuan. The relevant data in this forecast are preliminary calculations by the company’s financial department; the specific financial data will be based on the “2025 Annual Report” disclosed by the company. As of the date of this announcement, there is no need to revise the “2025 Performance Forecast.”

The company hereby reminds investors: “China Securities Journal,” “Securities Times,” “Shanghai Securities News,” “Securities Daily,” and Juchao Information Network are the designated information disclosure media of the company. All information published by the company is based on disclosures in these media. Investors are advised to invest rationally and be aware of risks.

This announcement is hereby made.

Board of Directors of Hunan Jingfeng Pharmaceutical Co., Ltd.

March 16, 2026

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.